Skip to main content
TipRanks
Go Ultimate75% OFF

OrthoPediatrics (KIDS) AI Stock Analysis

121 Followers
KIDS

OrthoPediatrics

(NASDAQ:KIDS)

Select Model
Rating:61Neutral
Price Target:$32.00â–²(1.59% Upside)
Action:reiterated
Date:10/29/26

The score is driven primarily by improving fundamentals (strong revenue growth, high gross margins, and a recent move to positive TTM operating/free cash flow) and a very constructive earnings update with raised revenue guidance and reiterated EBITDA/FCF targets. Offsetting these positives are the still-lossmaking profile (negative net margin and negative P/E) and technically overbought momentum indicators that increase near-term pullback risk.

Positive Factors
Strong Revenue Growth and Gross MarginsSustained revenue expansion alongside consistently high gross margins indicates strong demand for the pediatric-focused portfolio and meaningful product economics. This combination gives OrthoPediatrics resources to invest in commercial expansion, innovation, and surgeon adoption while supporting scalable growth.
Negative Factors
Persistent Net and Operating LossesDespite strong sales growth and narrowing losses, the company has not yet demonstrated durable earnings power. Persistent operating and net losses can constrain internally funded investment, leave profitability sensitive to expense growth, and make future performance dependent on continued operating leverage.

OrthoPediatrics (KIDS) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%KIDS+86.72%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$822.48M
Dividend Yield
―
Average Volume (3M)
281.22K
Price to Earnings (P/E)
-22.0
Beta (1Y)
0.70
Revenue Growth
16.15%
EPS Growth
27.21%
Country
US
Employees
602
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

OrthoPediatrics Business Overview & Revenue Model

Company Description

OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children af...

How the Company Makes Money

OrthoPediatrics primarily makes money by selling pediatric-focused orthopedic implants and the associated surgical instruments/sets used to implant them. Revenue is generated when hospitals and ambulatory surgery centers purchase the company’s steril...

OrthoPediatrics Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:32.24%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record revenue, 19% quarterly growth, a raised full-year revenue outlook, record adjusted EBITDA, positive quarterly free cash flow, strong demand across core businesses, and substantial progress in product launches and clinic expansion. The main challenges were that many super-cycle products remain in limited launch, eLLi commercialization is largely a 2028-2029 opportunity, year-to-date free cash flow remains negative, and operating expenses and commissions increased. Overall, the breadth and magnitude of the reported growth and management's confidence outweighed the timing and investment-related challenges.

Positive Updates

Record Quarterly Revenue and Broad-Based Growth
Third-quarter 2026 revenue reached a record $72.7 million, up 19% from $61.2 million in the prior-year period. Growth was driven by strong demand across implants and OPSB, trauma and deformity, scoliosis, international operations, legacy portfolio share gains, and new product contributions.

Negative Updates

Many Super-Cycle Products Are Still in Limited Launch
Many products in the super cycle remain in the very early stages of full market release or limited launch and are not yet meaningfully contributing to growth. Management said some products are not expected to contribute significant revenue in 2026.

Company Guidance

The company raised full year 2026 revenue guidance to the range of $270 million to $273 million, representing growth of 14% to 16%, reiterated adjusted EBITDA guidance of approximately $25 million, and continues to expect to deploy approximately $10 million in sets and achieve free cash flow break-even or better in 2026, with free cash flow positive in 2027 and beyond; year to date free cash flow was about $6 million of usage, requiring $6 million of positive free cash flow in the fourth quarter to reach breakeven or better for the year, and fourth-quarter gross margin was projected at 73%.

OrthoPediatrics Financial Statement Overview

Summary

Strong multi-year revenue growth with consistently high gross margins (low-to-mid 70s) is a clear positive, and TTM shows an inflection to positive operating cash flow ($12.5M) and positive free cash flow ($3.2M). However, profitability remains the key weakness (negative EBIT and meaningfully negative TTM net margin of -12.8%), and cash-flow consistency is not yet proven after multiple years of negative operating cash flow.

Income Statement

46Neutral

Balance Sheet

63Positive

Cash Flow

44Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue264.14M236.35M204.73M148.73M122.29M98.05M
Gross Profit194.84M172.66M148.60M111.25M90.66M73.40M
EBITDA2.43M-12.07M-20.23M-8.38M-8.69M-7.19M
Net Income-33.88M-39.65M-37.82M-20.97M1.26M-16.26M
Balance Sheet
Total Assets509.09M508.63M473.21M438.75M427.73M308.40M
Cash, Cash Equivalents and Short-Term Investments44.23M60.85M68.83M80.31M118.29M54.91M
Total Debt98.36M99.99M80.90M10.06M907.00K28.51M
Total Liabilities169.74M162.03M118.64M61.72M49.08M83.03M
Stockholders Equity339.35M346.60M354.57M377.02M378.65M225.37M
Cash Flow
Free Cash Flow3.18M-15.96M-41.31M-46.03M-31.80M-29.07M
Operating Cash Flow12.49M-4.85M-27.05M-27.05M-21.77M-13.06M
Investing Cash Flow-10.20M-43.63M-13.16M41.68M-113.37M-7.41M
Financing Cash Flow-3.30M23.98M53.13M7.30M135.97M6,000

OrthoPediatrics Technical Analysis

Technical Analysis SentimentPositive
Last Price31.50

Price Trends

50DMA25.25Positive
100DMA23.52Positive
200DMA20.35Positive

Market Momentum

MACD2.41Positive
RSI60.89Neutral
STOCH38.55Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KIDS, the sentiment is Positive. The current price of 31.50 is above the 20-day moving average (MA) of 29.72, above the 50-day MA of 25.25, and above the 200-day MA of 20.35, indicating a bullish trend. The MACD of 2.41 indicates Positive momentum. The RSI at 60.89 is Neutral, neither overbought nor oversold. The STOCH value of 38.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KIDS.

OrthoPediatrics Risk Analysis

OrthoPediatrics disclosed 79 risk factors in its most recent earnings report. OrthoPediatrics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Provisions in the indenture governing the Convertible Notes could delay or prevent an otherwise beneficial takeover of us.Q4, 2025
2.Changes in Medicaid coverage and reimbursement policies may adversely affect our business, financial condition, and results of operations.Q4, 2025
3.We are subject to risks of doing business in other countries, including those related to tariffs, trade restrictions and government actions.Q4, 2025

OrthoPediatrics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

KIDS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GMEDGMED73Outperform$9.34B17.0311.82%―13.35%32.22%
ZBHZBH69Neutral$19.19B25.656.05%0.95%6.98%-2.22%
KIDSKIDS61Neutral$822.48M-22.04-9.91%―16.15%27.21%
ENOVENOV58Neutral$1.61B-2.98-35.53%―3.28%62.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC50Neutral$1.05B-12.11-547.17%―15.34%46.31%
OFIXOFIX44Neutral$277.17M-6.14-10.32%―2.12%63.59%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%KIDSATECENOVOFIXZBHGMEDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KIDS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KIDSOrthopediatrics Corp31.5014.8889.53%
ATECAlphatec6.78-12.84-65.44%
ENOVEnovis Corporation27.920.752.76%
OFIXOrthofix Medical Inc.6.80-7.66-52.97%
ZBHZimmer Biomet Holdings101.4112.9114.58%
GMEDGlobus Medical70.50-13.32-15.89%

OrthoPediatrics Corporate Events

Business Operations and StrategyFinancial Disclosures

OrthoPediatrics Highlights Pediatric-Focused Strategy in Investor Deck

Positive
Oct 27, 2026

OrthoPediatrics Corp.’s executive team has scheduled upcoming presentations to investors and analysts in which they will use a 2026 investor deck outlining their pediatric-focused business model and financial metrics. The presentation reiterates the...

Business Operations and StrategyFinancial Disclosures

OrthoPediatrics Highlights Growth in 2026 Investor Presentations

Positive
Aug 4, 2026

OrthoPediatrics’ executive officers plan upcoming presentations to investors and analysts using a new 2026 investor deck that highlights the company’s pediatric-only focus and outlines its use of non-GAAP metrics such as free cash flow, adjusted dilu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026